NCT05063955Recruiting
Mechanism of Sarcopenia in Heart Failure
Socioeconomic Factors and Mechanisms of Sarcopenia and Muscle Strength in Chronic Heart Failure Patients
Source: ClinicalTrials.gov · Last updated 26 Dec 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aim of the study is to provide information on the interaction between socioeconomic factors, daily physical activity, nutrition and lifestyle on loss of muscle mass and muscle function in patients with heart failure.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 1 Jun 2021
- Start date
- 2 Dec 2020
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Aarhus University Hospital
- Diseases
- Heart failure
- NCT number
- NCT05063955
What you commit to
- Study type: Observational
- Planned participants: 250
- From 2 Dec 2020 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Severe lung disease with a forced expiratory volume 1 \< 40% of predicted. Treatment with anticoagulants (warfarin, apixaban, edoxaban, dabigatran and rivaroxaban) is an exclusion criterion for muscle biopsy. Patients with anticoagulant treatment will be invited to participate in the study without muscle biopsy.
Other illness
- Cancer requiring treatment (e.g. prostate cancer on watchful waiting does not exclude patients).
Other
- Severe musculoskeletal or neurological disability.
- Other comorbidities that prevent the patient from participating in the study examinations as judged by the investigator.
Who the study is looking for
- Ability to provide valid informed consent.
- Heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.
Age in the registry: 18 years to 90 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aarhus University Hospital Coordinator of this site? Confirm its status | Aarhus N | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.